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Background: Opioids may have effects on susceptibility to HIV-infection, viral replication and disease progression.
Injecting drug users (IDU), as well as anyone receiving opioids for anesthesia and analgesia may suffer the clinical
consequences of such interactions. There is conflicting data between in vitro experiments showing an enhancing
effect of opioids on HIV replication and clinical data, mostly showing no such effect. For clarification we studied the
effects of the opioids heroin and morphine on HIV replication in cultured CD4-positive T cells at several concentrations
and we related the observed effects with the relevant reached plasma concentrations found in IDUs.
Methods: Latently-infected ACH-2 T lymphoblasts were incubated with different concentrations of morphine and
heroine. Reactivation of HIV was assessed by intracellular staining of viral Gag p24 protein and subsequent flow
cytometric quantification of p24-positive cells. The influence of the opioid antagonist naloxone and the antioxidants
N-acetyl-cysteine (NAC) and glutathione (GSH) on HIV reactivation was determined. Cell viability was investigated by
7-AAD staining and flow cytometric quantification.
Results: Morphine and heroine triggered reactivation of HIV replication in ACH-2 cells in a dose-dependent manner at
concentrations above 1 mM (EC50 morphine 2.82 mM; EC50 morphine 1.96 mM). Naloxone did not interfere with
heroine-mediated HIV reactivation, even at high concentrations (1 mM). Opioids also triggered necrotic cell
death at similar concentrations at which HIV reactivation was observed. Both opioid-mediated reactivation of
HIV and opioid-triggered cell death could be inhibited by the antioxidants GSH and NAC.
Conclusions: Opioids reactivate HIV in vitro but at concentrations that are far above the plasma levels of
analgesic regimes or drug concentrations found in IDUs. HIV reactivation was mediated by effects unrelated
to opioid-receptor activation and was tightly linked to the cytotoxic activity of the substances at millimolar
concentrations, suggesting that opioid-mediated reactivation of HIV was due to accompanying effects of cellular
necrosis such as activation of reactive oxygen species and NF-κB.
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Many of the HIV-infected individuals who inject intraven-
ous drugs consume morphine, heroin or related sub-
stances. There is conflicting data on the impact of opioids
on HIV disease progression. Whereas in vitro studies sug-
gest a potential link between opioid exposure and elevated
virus replication or decreased immune function [1-5],
most of epidemiological and clinical studies do not find a
correlation between opioid intake and progression of HIV
infection [6-12]. In order to reconcile these conflicting* Correspondence: Johannes.Prottengeier@kfa.imed.uni-erlangen.de
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article, unless otherwise stated.data, we performed in vitro experiments studying the ef-
fects of opioids (heroin and morphine) on HIV replication
in the chronically-infected CD4-positive T cell line ACH-2
[13]. CD4-positive T cells represent the cellular reservoir
in which HIV is harbored predominantly in the body and
they contribute to most of the viral replication detected in
the blood plasma [14-16].Results
Morphine and heroine reactivate HIV in ACH-2 cells
In order to investigate the effects of the opioids heroine
and morphine on reactivation of proviral HIV in latently-
infected T cells, we incubated ACH-2 cells with differentntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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incubation for 24 h we measured intracellular HIV-p24
protein expression by flow cytometry. We found a dose-
dependent reactivation of HIV for morphine (Figure 1A)
and heroine (Figure 1B). The EC50 concentrations for
the two substances were 2.82 mM and 1.96 mM, respect-
ively (Figure 1). Figures 1C and D display representative
dot-plots analyzing p24-expression (y-axis) of untreated
(Figure 1C) or 4 mM heroin-treated (D) cells. The back-
ground expression visible in Figure 1C is typical for ACH-
2 cells and originates from intrinsic stimulation of the
cells. We also tested the effects of heroin on HIV replica-
tion at very low concentrations, similar to the plasmaFigure 1 Opioids activate HIV replication in vitro. Latently-HIV-infected
different concentrations of morphine (A) or heroin (B). HIV replication was
C, D: representative dot-plot analyses of ACH-2 cells left untreated (C) or treat
the y-axis displays p24-expression. Pink rectangles represent the gates
proportion (%) of p24-positive cells from the total number of events. E
in plasma of IDUs (1-10 μM). F: Latently-HIV-infected ACH-2 T lymphob
together with different concentrations of naloxone (0 μM and 0.1μM –
HIV p24-antigen and flow cytometry. Data as mean ± S.E.M. from dupl
positive and significantly differ from = zero (p = 0.0008 for medium anconcentrations found in IDUs and found no activating ef-
fects (Figure 1D).
Naloxone does not inhibit heroine-mediated reactivation
of HIV
Opioid receptor signaling has been described on lympho-
cytes [1] and opioid receptors that bind the opioid antag-
onist naloxone have been identified on T cells (reviewed
in [17]). We therefore investigated whether the observed
HIV-activating effect of opioids was mediated by opioid-
specific receptor stimulation. For that we triggered
HIV reactivation with heroine in the absence or presence
of different concentrations of naloxone. As depictedACH-2 T lymphoblasts were cultured for 24 hours in the presence of
quantified by intracellular staining of HIV p24-antigen and flow cytometry.
ed with 4 mM heroin (D). The x-axis displays the forward scatter,
for p24-positive cells and the small numbers within indicate the
: Heroin has no effects on HIV reactivation at concentrations found
lasts were cultured for 24 hours in the presence of 5 mM heroin,
1 mM). HIV replication was quantified by intracellular staining of
icates and linear regression. The slopes of both regressions are
d p = 0.0152 for heroin).
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mediated HIV reactivation, indicating that opioid receptor-
independent mechanisms account for the observed effects.
NAC and GSH inhibit opioid-mediated HIV reactivation
Heroin- and morphine-mediated activation of HIV repli-
cation was completely prevented by the antioxidants
N-acetylcystein (NAC) or reduced glutathione (GSH)
(Figure 2), indicating that oxidative stress might be
involved in opioid-mediated reactivation of HIV. The
relatively high opioid concentrations needed to stimulate
HIV replication were also associated with induction of
necrotic cell death. A3.01 T cells, the uninfected parental
cell line of ACH-2 cells, showed a significant amount of
necrosis induction following treatment with 2.5 mM
heroin as assessed by staining with the cell dye 7-AAD
(Figure 3A). This necrosis induction could again be
completely prevented by the antioxidant N-acetylcystein
(Figure 3A). We used for this experiment the uninfected
parental cell line because the 7-AAD dye requires non-
fixated cells, which in case of the HIV-infected ACH-2
cells we could not subject to our flow cytometer for safety
reasons. In order to demonstrate that ACH-2 cells react
in a similar way to opioids as A3.01 cells, we analyzed
cell death in ACH-2 cells by a characteristic shift of the
cell population in the forward-scatter/sideward-scatter
dot plot analysis, which correlates with 7-AAD-staining.
This shift is depicted in Figure 3C from representative
analyses for different heroin concentrations. The corre-
sponding p24-expression profiles are depicted in Figure 3D.
As shown in Figure 3B, activation of HIV in ACH-2 cellFigure 2 Antioxidants inhibit opioid-mediated reactivation of HIV. Lat
with of heroin (A, C) or morphine (B, D) in the presence or absence of th
HIV replication was quantified by intracellular staining of HIV p24-antigcompletely paralleled with opioid-triggered necrosis. We
reported earlier that necrotic signaling triggers NF-κB and
HIV-reactivation in ACH-2 T lymphoblasts [18]. These
data indicate that the observed opioid-mediated activation
of HIV replication was secondary to the opioid-triggered
necrosis observed at high concentrations.
Discussion
Opioid-mediated reactivation of latent HIV infection in
our model was observed at concentrations in the lower
millimolar range. Since opioids are common in the HIV-
risk group of injecting drug users (IDUs), this activity
might influence the pathogenesis of HIV infection in this
group of patients. However, plasma concentrations of
heroine in IDUs are in the range of 1–10 μM [19] and
even maximum plasma concentrations are only in the
range of 1500–3900 ng/ml (reviewed in [20]), which cor-
responds to 4.1-10.7 μM (calculated with a molar weight
of 369.41 g/mol). Secondly plasma-concentrations of
medically administered morphine and its modern deri-
vates for means of analgesia remain well below those
ranges of reactivating effects [21-23]. These in vivo con-
centrations are 2–3 orders of magnitude lower than the
in vitro concentration at which we observed a stimulat-
ing effect. It therefore seems very unlikely that the here-
described opioid-mediated reactivation of HIV may have
any influence on HIV replication in vivo.
Opioid-triggered reactivation of HIV replication in
latently-infected cells has been described in the mono-
cytic cell line U1 [3]. HIV reactivation after treatment
with morphine was observed in the picomolar (10−12)ently-HIV-infected ACH-2 T lymphoblasts were cultured for 24 hours
e antioxidants N-acetylcystein (NAC) (A, B) or glutathione (C, D).
en and flow cytometry.
Figure 3 Opioid-mediated reactivation of HIV is tightly linked to cellular necrosis. Latently-HIV-infected ACH-2 T lymphoblasts were cultured
for 24 hours with of heroin in the presence or absence of glutathione. HIV replication was quantified by intracellular staining of HIV p24-antigen and
flow cytometry (A). Cell viability was assessed by FSC/SSC-analysis in flow cytometry (B). Representative dot plots of cell viability analysis
(C) and p24-expression (D) at different heroin concentrations. Pink rectangles on the right represent the gates for p24-positive cells and
the small numbers within indicate the proportion (%) of p24-positive cells from the total number of events. Pink regions on the left represent the
gates for living and necrotic cells and the small numbers within indicate the proportion (%) of events within the region from the total number of events.
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micromolar concentrations – the concentration range of
plasma levels found in drug abusers - no effects were
observed [3]. Similar effects were reported from the
same group when studying productive infection in cul-
tured peripheral blood lymphocytes [4]. In studies withexperimental SHIV-infection in the rhesus macaque
model, elevated viral load was reported in morphine-
treated animals (n = 6) versus untreated animals (n = 3)
[2]. Recently, a decrease in anti-HIV microRNA expres-
sion was reported in monocytes following treatment
with morphine and heroin [5], suggesting a potential
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in vitro studies.
In contrast, the majority of epidemiological studies does
not show negative effects of drug abuse on HIV progres-
sion [8-12], but many confounding variables such as the
pattern of drug use may make it difficult to clearly inter-
pret this data. To address this, a prospective clinical study
with a total of 1148 participants was performed, in which
the effects of hard drug use (opioids or cocaine) on HIV
disease parameters was studied [6]. Drug use had no effect
on HIV viral load or CD4 cell counts (n = 613 versus n =
535). In line with this, no effects of drug use on viral load
have been observed in a seroconverter study with 60 injec-
tion drug users in a total of 149 participants [7].
The literature therefore seems to be divided into ex-
perimental and in vitro studies reporting enhancement
of HIV infection following treatment with opioids and
in vivo studies not finding such a correlation. We sug-
gest that this difference, at least in parts, relates to the
concentration range at which effects were observed: All
in vitro studies reporting an HIV-activating effect of opi-
oids in cell culture found these effects at very low concen-
trations and no activity was observed at relevant plasma
concentrations [3-5]. Moreover, all so-far reported in vitro
data were generated in monocytes [3,5] (or in PBMC con-
taining monocytes [4]), whereas more than 99% of HIV
particles detected in the human plasma originate from T-
lymphocytes [15,24,25]. Hence, effects found in monocytes
in vitro may not be representative for the lymphocyte-
driven plasma viral load in vivo. Our in vitro-results indi-
cate that there is an HIV-stimulating effect of opioids also
in T cells, but only at concentrations that are far above
relevant in vivo-concentrations. The molecular mechanism
of HIV latency in the ACH-2 cell line used in our study is
caused by a defect in the Tat/TAR axis [26] and the same
mechanism of latency is also frequently found in latently-
infected primary T cells isolated from HIV patients [27].
Taken together, the literature seems to be divided into
in vitro studies reporting enhancement of HIV infection
following treatment with opioids and in vivo studies not
finding such a correlation. Our in-vitro results indicate
that there is an HIV-stimulating effect of opioids in
latently-infected T cells, but only at concentrations that
are far beyond relevant in vivo-concentrations and our
findings may therefore contribute to reconcile the appar-
ently conflicting data of in vitro and in vivo research. Our
data provides no evidence that the medical use of opioids
for indications of anesthesia and analgesia in HIV-infected
patients may have any side effects on HIV replication.
Conclusion
Opioids reactivate HIV in vitro but at concentrations
that are far above the plasma levels of analgesic regimes
or drug concentrations found in IDUs. HIV reactivationis mediated by effects unrelated to opioid-receptor acti-
vation and seems tightly linked to the cytotoxic activity
of these substances at a millimolar level, suggesting that
opioid-mediated reactivation of HIV is due to accom-
panying effects of cellular necrosis such as activation of
reactive oxygen species and NF-κB.
Materials and methods
Cell culture
A3.01 (human CD4 + −T-lymphoblasts, NIAID) and ACH-
2 (latently HIV-infected A3.01, Folks 1989, NIAID) were
cultured in standard tissue flasks using RPMI-medium
(Invitrogen, Karlsruhe, Germany) supplemented with 10%
FCS (Linaris, Bettingen, Germany) at 37°C and 5% CO2
atmosphere. Peripheral blood mononuclear cells (PBMC)
were isolated by Ficoll/Paque density-separation centrifu-
gation from human whole blood donated by healthy volun-
teers. For the different experiments 105 cells per well were
cultured in flat-bottom 96 well plates in a total volume of
200 μl for 24 h in the absence or presence of the indicated
substances.
Opioids, antagonists and other reagents
Morphine and Heroine were obtained from the University
of Wurzburg’s Department of Forensic Medicine. The Use
and Discard of those substances were documented in
accordance with the German Narcotics Act. Naloxone,
Glutathion and N-Acetylcysteine were purchased through
Sigma, St.Lewis, MO.
Flow cytometry
Reactivation of HIV in ACH-2 cells was quantified by the
expression of viral p24-antigen detected by flow cytometry
(Becton-Dickinson, Heidelberg, Germany). Cells were fix-
ated for 20 min with 4% formalin in PBS and later perme-
abilized with 0.5% saponin in PBS/5%BSA. The following
antibodies were used: 183-H12-5C-anti-HIV-p24-mouse-
antibody and goat-anti-mouse antibodies conjugated with
FITC or PE (BD Biosciences). Cell death in uninfected
A3.01 cells was quantified by 7-AAD staining according to
the instructions of the manufacturer (BD Biosciences). Be-
sides staining with 7-AAD, necrotic cells also displayed a
characteristic shift in a forward-scatter (FSC)/sideward scat-
ter (SSC) dot plot. This shift was used to quantify necrotic
cells also for HIV-infected ACH-2 cells, for which a 7-AAD
staining was not possible for safety reasons (7-AAD stain-
ing requires nonfixated cells which in case of ACH-2 cells
would contaminate the flow cytometer with HIV).
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